Study of MBS303 for CD20-positive B-cell lymphoma that returned
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older and able to sign consent and follow the study plan
- You must have CD20-positive B-cell non-Hodgkin lymphoma that returned after or did not respond to at least one prior anti-CD20 treatment
- Your body movement/energy level must be good (ECOG 0 or 1), and you should have at least 3 months to live
- You must have measurable lymphoma spots on scans or exams (large enough nodal or extranodal lesions)
- Your blood counts, liver, and kidney tests must meet required limits
- You must not have certain other lymphoma types, major recent cancer treatments, or serious active medical problems or infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This study tests a new experimental drug called SCTB35 for people with B-cell lymphoma that has come back or stopped responding to treatment. The drug is designed to target a protein on cancer cells (CD20) and may help your immune system fight the lymphoma.
This study tests a new drug called CN201 (also known as MK-1045) for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
This Phase 1 study tests an investigational treatment for adults with lymphoma that has come back or did not respond to prior treatments. It targets lymphoma cells that have CD19 and CD20 markers, aiming to reduce or control the disease in people with limited options.
This trial tests an experimental drug called BTM-3566 in people with a type of lymphoma that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Hear when a new Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.